Investors & Media

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome

Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part 2, the long-term extension portion of the study Encouraging EEG and clinical observations support

Read more
You are now leaving to visit